Oncolytics Biotech Inc ONCY

Primary Symbol: T.ONC

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Quentin30 is a pathological prevaricator.

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon Apr 15, 2024 2:13pm

150 Views

Post# 35989867

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Quentin30 is a pathological prevaricator.

With respect to " ...someone needs to talk to Allison and.straigjten her out hey note and btw no AA until after the phase 3.trials start..." I agree, however, ONCY or it acquirer, only needs demonstrate that the Phase 3/4 post confirmatory trial is well into the trial's patient registration initiative to have the FDA grant Accelerated Approval.

<< Previous

Bullboard Posts

Next >>

What will the U.S. election results mean for Canada?